The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Gilead Sciences (I); SERVIER
Consulting or Advisory Role - Merck Serono; SERVIER
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); CellCentric (Inst)
Travel, Accommodations, Expenses - SERVIER
A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Christina Guo
No Relationships to Disclose
 
Simon J. Crabb
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Merck; Pfizer
Consulting or Advisory Role - Amphista Therapeutics; Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Janssen; Merck; Novartis; Pfizer; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Roche
Expert Testimony - Merck/Pfizer; MSD
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen; Merck; Merck
 
Simon Pacey
Consulting or Advisory Role - AstraZeneca (Inst); Elsevier (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Guardant Health (Inst)
 
Vicky Coyle
No Relationships to Disclose
 
Sarah Danson
Consulting or Advisory Role - Orion; Oxcia
Research Funding - Amgen; AstraZeneca; MSD; Roche; Scancell Ltd.; Sun Pharma
 
Guillermo Villacampa
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - GlaxoSmithKline; MSD; Pfizer; Pierre Fabre
 
Khobe Chandran
No Relationships to Disclose
 
Alec Paschalis
Patents, Royalties, Other Intellectual Property - Named on patent held by the Institute of Cancer Research (ICR) together with Cancer Research UK identifying JMJD6 as a therapeutic target in advanced prostate cancer. (Inst)
 
Ruth Riisnaes
No Relationships to Disclose
 
Ana Ferreira
No Relationships to Disclose
 
Suzanne Carreira
No Relationships to Disclose
 
Claudia Bertan
No Relationships to Disclose
 
Mateus Crespo
No Relationships to Disclose
 
Ines Figueiredo
No Relationships to Disclose
 
Ruth Matthews
No Relationships to Disclose
 
Alison Joanne Turner
No Relationships to Disclose
 
Christina Yap
Honoraria - Bayer
Consulting or Advisory Role - Faron Pharmaceuticals
Travel, Accommodations, Expenses - Faron Pharmaceuticals
 
Andrea Alimonti
Stock and Other Ownership Interests - Bottega Organica; Oncosense
Research Funding - Dompé Farmaceutici (Inst); IBSA (Inst)
Patents, Royalties, Other Intellectual Property - Fondazione Per L'istituto Oncologico Di Ricerca, Altergon, Arbormentis; Fondazione Per L'istituto Oncologico Di Ricerca, Altergon, Arbormentis (Inst)
(OPTIONAL) Uncompensated Relationships - Astellas Pharma; AstraZeneca; Global FZE; Sun Pharma
 
Adam Sharp
Honoraria - Astex Pharmaceuticals; MSD
Consulting or Advisory Role - Charm Therapeutics; D. E. Shaw Research
Travel, Accommodations, Expenses - Nurix; Roche/Genentech; Sanofi
 
Johann S. De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi Aventis GmbH
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Harpoon (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi